News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
22.05.2019 07:15:03

Press Release: Novartis phase II data for new -2-

such products will be commercially successful in the future. In

particular, our expectations regarding such products could be affected

by, among other things, the uncertainties inherent in research and

development, including clinical trial results and additional analysis of

(Anzeige)Passende neue Barrier Reverse Convertibles

Basiswert Valor Barriere in % Coupon in %
Nestlé / Novartis / Roche GS 48130271 69.00 % 5.50 %
Nestlé / Novartis / Roche GS 48130272 59.00 % 4.25 %

existing clinical data; regulatory actions or delays or government

regulation generally; global trends toward health care cost containment,

including government, payor and general public pricing and reimbursement

pressures and requirements for increased pricing transparency; our

ability to obtain or maintain proprietary intellectual property

protection; the particular prescribing preferences of physicians and

patients; general political and economic conditions; safety, quality or

manufacturing issues; potential or actual data security and data privacy

breaches, or disruptions of our information technology systems, and

other risks and factors referred to in Novartis AG's current Form 20-F

on file with the US Securities and Exchange Commission. Novartis is

providing the information in this press release as of this date and does

not undertake any obligation to update any forward-looking statements

contained in this press release as a result of new information, future

events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach more than 750 million people

globally and we are finding innovative ways to expand access to our

latest treatments. About 105 000 people of more than 140 nationalities

work at Novartis around the world. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at


For Novartis multimedia content, please visit


For questions about the site or required registration, please contact



[1] Watz, H et al. The Combination of

Indacaterol/Glycopyrronium/Mometasone Furoate is Superior to High-Dose

Salmeterol/Fluticasone Propionate in Improving Lung Function in Patients

with Asthma. ATS abstract 2019

[2] Beier, J et al. The Efficacy of the Combination

Indacaterol/Glycopyrronium/Mometasone Furoate is Independent of Time of

Dosing in Patients with Asthma. ATS abstract 2019

[3] NIH: ClinicalTrials.gov. Assess Bronchodilator Effect and Safety

of Two Doses of QVM149 Compared to a Fixed Dose Combination of

Salmeterol/Fluticasone in Patients With Asthma. Available at:


Accessed April 2019

[4] NIH: ClinicalTrials.gov. Assess Bronchodilator Effect QVM149 Dosed

Either in the Morning or Evening Compared to Placebo in Patients With

Asthma (QVM149). Available at:


Accessed April 2019

[5] BD Chronic Respiratory Disease Collaborators. Global, regional,

and national deaths, prevalence, disability-adjusted life years, and

years lived with disability for chronic obstructive pulmonary disease

and asthma, 1990-2015: a systematic analysis for the Global Burden of

Disease Study 2015. Lancet Respir Med 2017: 5(9): 691-706.

[6] Global Inititative for Asthma. Global Strategy for Asthma

Management and Prevention, 2018. Available from

http://ginasthma.org/gina-reports/. Accessed in April 2019

[7] Fang J, Busse W, Marvel J, Tian H, Altman P, Cao H. Demographic,

clinical characteristics and control status of pediatric, adolescent,

and adult asthma patients by GINA Step in a US longitudinal cohort. Am J

Resp Crit Care Med 2018: 197:A1903.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Peter Zuest Beyza Oezel

Novartis Global External Communications Global Head, Respiratory Communications

+41 79 899 9812 (mobile) +41 61 696 9503 (direct)

peter.zuest@novartis.com +41 79 720 4038 (mobile)

Eric Althoff beyza.oezel@novartis.com

Novartis US External Communications

+1 646 438 4335


Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Richard Pulik +1 862 778 3275

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 862 778 3258

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

Media release (PDF): http://hugin.info/134323/R/2244904/886586.pdf

This announcement is distributed by West Corporation on behalf of West

Corporation clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Novartis International AG via Globenewswire

--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267;


(END) Dow Jones Newswires

May 22, 2019 01:15 ET (05:15 GMT)